<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Plenk</id>
	<title>Plenk - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Plenk"/>
	<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Plenk&amp;action=history"/>
	<updated>2026-10-04T13:35:58Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>http://hboevidence.wikis.unsw.edu.au/index.php?title=Plenk&amp;diff=192&amp;oldid=prev</id>
		<title>Gordoben: Imported from Wikispaces</title>
		<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Plenk&amp;diff=192&amp;oldid=prev"/>
		<updated>2011-12-31T02:34:00Z</updated>

		<summary type="html">&lt;p&gt;Imported from Wikispaces&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;'''The conduct of radiotherapy in an environment of hyperbaric oxygenation improved survival in carcinoma of the urinary bladder.''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Bottom Line:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. The addition of hyperbaric oxygenation to a regime of radiotherapy for cancer of the bladder resulted in a significant reduction in mortality over two years. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Mortality was high in both groups. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Appraised by:''' Mike Bennett, Dept of Diving and Hyperbaric Medicine, Prince of Wales Hospital &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Sydney; Friday, 11 December, 1998 &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Scenario:''' A patient with bladder cancer where radiotherapy is the treatment of choice. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Three-part Question:''' In urinary bladder carcinoma being treated with radiotherapy, does exposure to the radiation dose while having hyperbaric oxygen, compared to normal air breathing, result in any improvement in recurrence rate, mortality or morbidity? &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Search Terms:''' Hyperbaric oxygenation, radiotherapy, tumours/bladder. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Non-blinded randomised controlled trial with intention-to-treat. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Patients with staged bladder cancer presenting for radiotherapy. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Control group (N = 21; 21 analysed): 6,000 rads over six weeks, giving four or five fractions each week. No attempt to sham treatment. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Experimental group (N = 19; 19 analysed): 4,800 rads over 29-32 days in 12 fractions while breathing 100% oxygen at 3ATA for about 40 minutes. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Evidence:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| &lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Outcome''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Time to Outcome''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Air Group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''HBO Group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Relative risk reduction''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Absolute risk reduction''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''NNT''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Survival''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;6 months &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.810 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.895 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;10% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.09 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;12 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-16% to 37% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.13 to 0.30 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNT'''3 to INF NNH'''8 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Survival''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;48 months &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.048 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.105 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;119% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.06 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;18 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;100% to -100% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.11 to 0.22 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNT'''4 to INF NNH'''9 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Non-Event O''''''utcomes'''&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Outcome Time to outcome P-value''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;Survival &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;analysis 0-27 months P&amp;lt;0.05&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Comments:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Small study did not show significant differences at point estimates of survival. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Radiotherapy regime was different between the two groups. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. The significance for present treatment of bladder cancer is not clear. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Expiry date:''' January 2004 &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''References:''' 1. Plenk HP. Hyperbaric radiation therapy. Preliminary results of a randomised study of cancer of the urinary bladder and review of the 'oxygen experience'. Am J Roentgenol Radium Ther Nucl Med. 1972; 114:152-157. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
[[File:http://www.hboevidence.com/_themes/copy-of-sumi-painting/sumhorsa.gif]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;color: #7c00ff; font-family: Arial,Helvetica,sans-serif; font-size: 26px;&amp;quot;&amp;gt;[[DXRTpelvis  |  BACK]]&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt;&lt;/div&gt;</summary>
		<author><name>Gordoben</name></author>
		
	</entry>
</feed>